Physician profile
John Mccarthy
NPI 1477662179
$8,287.80
in general payments reported to CMS, 2019-2025
52 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $424 · 2021: $1,189 · 2022: $1,376 · 2023: $1,837 · 2024: $1,328 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,385 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,384.70 |
| Education | $108.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $904.15 | 2019-2025 | Myrbetriq, Xtandi |
| Myriad Genetic Laboratories, INC. | $681.01 | 2021-2025 | Prolaris |
| Janssen Biotech, INC. | $656.75 | 2019-2025 | Erleada, Akeega, Carvykti |
| Sumitomo Pharma America, INC. | $516.35 | 2023-2025 | Gemtesa, Orgovyx |
| Accord Healthcare, INC. | $441.31 | 2022-2024 | |
| Pfizer INC. | $420.28 | 2019-2025 | |
| Antares Pharma, INC. | $357.04 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Boston Scientific Corporation | $353.77 | 2019-2023 | |
| Urogen Pharma, INC. | $343.77 | 2023-2025 | Jelmyto |
| Dendreon Pharmaceuticals LLC | $339.22 | 2020-2025 | Provenge |
| Merck Sharp & Dohme LLC | $328.73 | 2020-2024 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $282.32 | 2019-2025 | |
| Allergan, INC. | $208.51 | 2019-2021 | |
| Abbvie INC. | $205.21 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $198.60 | 2019-2025 | Adstiladrin |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.